Clinical Trial

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\[177Lu\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-07-11; most recent amendment 2025-08-28.
Status change: Recruiting → Active, Not Recruiting 2024-07-21
Status change: Not Yet Recruiting → Recruiting 2022-12-25
Trial Details
NCT Number NCT05459844
Lead Sponsor Sinotau Pharmaceutical Group
Conditions Neuroendocrine Tumors
Enrollment 196 participants
Start Date 2022-08-31
Primary Completion 2024-06-26 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-05